Name: Clinical Research Center of Thrombosis and Hemostasis
Person in Charge: Hu Yu
Brief Introduction: Founded in 2007, Hubei Clinical Research Center of Thrombosis and Hemostasis is the first thrombosis and hemostasis research center in Central and Southern China, focused on the clinical and basic research of thrombus and hemostasis diseases, using cutting-edge technology and multidisciplinary integration to explore and develop methods for the early diagnosis, treatment and monitoring of thrombus and hemorrhagic diseases, and has carried out a series of research work. In clinical research, the center has undertaken a number of national key scientific research projects, obtained several NSFC funded projects, and established a supporting platform for the diagnosis and treatment of thrombosis and hemostasis diseases (the research platform of the development of major new drugs), a key laboratory of bio-targeted therapy accredited by the Ministry of Education, an innovation team for bio-targeted therapy of major diseases accredited by the Ministry of Education, etc., designed to provide an experimental platform and technical support for the related clinical and basic research of hospitals in the province.
In terms of basic research, the center is devoted to early diagnosis of thrombotic diseases and analysis on genetic factors. For the first time, the research team identified common genetic risk factors closely related to thrombotic diseases in the Chinese population and realized the early diagnosis of high-risk population through high-throughput molecular screening, which has been applied for a patent. The center has the largest VTE biobank in China. By using target area capture sequencing, common genetic polymorphisms and mutation sites associated with venous thrombus in Chinese people have been found and reported for the first time, and further realized the genetic screening and systematic risk assessment for the high-risk group of thrombosis, which help to identify the cause of thrombus for a large number of patients and increase the rate of early thrombosis diagnosis by 38%. The research achievement won the second prize of the National Science and Technology Progress Award.
In terms of developing a new nano-targeted drug delivery system with aiming at blood coagulation-related molecules, the center has successfully realized the targeted intervention of cerebral thrombosis by systemic drug delivery, and the research results have obtained three invention patents, which are actively transformed into pre-clinical practice. This technique lays a foundation for the clinical application of gene targeting therapy for thrombotic diseases and provides a scientific basis for the early diagnosis of thrombosis, the formulation of anticoagulant strategies and the selection of drugs, which is the first applied in the world.
In recent years, the center has further carried out research on myeloma and angiogenesis, and the research results have won the first prize of Hubei Science and Technology Progress Award. In terms of clinical diagnosis and treatment, the center has established a mode of "multidisciplinary cooperative diagnosis and treatment of thrombus", and formulated the Hubei Guidelines for the VTE Prevention and Treatment in Hospitals. The center instructs patients to choose anticoagulant drugs and determine the duration of anticoagulation, with realizing individualized standardized treatment. With measures of early prevention, targeted thrombolysis, surgical thrombectomy, filter implantation, anticoagulant monitoring, etc., the effective rate of thrombosis treatment all reach above 94%. In 2018, the center was awarded the national "Excellent Demonstration Base for Thrombosis Prevention and Treatment".
The center took the lead in establishing important indicators for DIC laboratory diagnosis in China, which presided over the formulation of diagnostic and therapeutic evaluation criteria for disseminated intravascular coagulation (DIC), presided over the formulation of domestic criteria for the diagnosis and efficacy of DIC and the criteria for the early diagnosis of DIC, and wrote the first monograph on DIC in China. Over recent years, the center has been expanding in clinical research, which formulated and improved China Guidelines for theDiagnosis and Treatment of Disseminated Intravascular Coagulation, and chaired the writing of Chinese expert consensuses on DIC diagnosis in 2012 and 2017. Through more than 5 years of multi-center research, the China Diagnostic Scoring System (CDSS) of DIC was established for the first time.
